Vilazodone

Last updated

Vilazodone
Vilazodone.svg
Clinical data
Pronunciation /vɪˈlæzədoʊn/
vi-LAZ-ə-dohn
Trade names Viibryd
Other namesEMD-68843; SB-659746A
AHFS/Drugs.com Monograph
MedlinePlus a611020
License data
Routes of
administration 		By mouth
Drug class Serotonin modulator [1]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 72% (oral, with food) [5]
Metabolism Liver via CYP3A4 [5]
Elimination half-life 25 hours [5]
Excretion Faecal and renal [5]
Identifiers
  • 5-(4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H27N5O2
Molar mass 441.535 g·mol−1
3D model (JSmol)
  • N#Cc5ccc4[nH]cc(CCCCN3CCN(c2ccc1oc(C(N)=O)cc1c2)CC3)c4c5
  • InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32) Yes check.svgY
  • Key:SGEGOXDYSFKCPT-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. [1] It is classified as a serotonin modulator and stimulator [1] and is taken by mouth. [1]

Contents

Common side effects include nausea, diarrhea, and trouble sleeping. [1] Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, mania, pancreatitis, and SIADH. [1] Vilazodone may cause less emotional blunting than typical SSRIs and SNRIs. [6] A withdrawal syndrome may occur if the dose is rapidly decreased. [1] Use during pregnancy and breastfeeding is not generally recommended. [7] It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT1A receptor. [1]

Vilazodone was approved for medical use in the United States in 2011 [1] and in Canada in 2018. [8] In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. [9] The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics. [10] Generic versions have been approved by the U.S. Food and Drug Administration (FDA). [11] [12]

Medical uses

Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder (MDD). [13] Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. [13] In the remaining two trials, small but significant advantages of vilazodone over placebo were found. [13] According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. [14] After eight weeks it resulted in a 13% greater response than placebo. [14] Remission rates, however, were not significantly different versus placebo. [14]

According to the US Food and Drug Administration (FDA) staff in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." [15] A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants." [16]

Development of vilazodone for generalized anxiety disorder (GAD) has been stopped as of 2017. [17] While there is tentative evidence of a small benefit in GAD, there is a high rate of side effects. [18]

Adverse effects

In September 2016, the FDA wrote a letter to Forest Labs requiring a new warning to be added to the label related to a link between the drug and acute pancreatitis and sleep paralysis. [19]

The most common adverse effects include nausea, diarrhea, vomiting, and insomnia. [5]

After a one-year, open-label study assessing the safety and tolerability of vilazodone in people with major depressive disorder, the most common adverse effects were diarrhea (35.7%), nausea (31.6%), and headache (20.0%); greater than 90% of these adverse effects were mild or moderate. [20] [14] In randomized controlled trials, meanwhile, these rates were 28%, 23.4% and 13.3%, respectively. [14] In contrast to other SSRIs, initial trials showed that vilazodone did not cause decreased sexual desire/function, which often cause people to abandon their use. [21] [ unreliable medical source? ] Additionally, vilazodone may cause less emotional blunting than typical SSRIs and SNRIs. [6]

Pregnancy

Antidepressant exposure (including vilazodone) is associated with shorter average duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points). [22] [23] It is uncertain whether there is an increased rate of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy. [24] [25]

Pharmacology

Pharmacodynamics

Vilazodone acts as a serotonin reuptake inhibitor (IC50 = 2.1 nM; Ki = 0.1 nM) and 5-HT1A receptor partial agonist (IC50 = 0.2 nM; IA = ~60–70%). [14] [26] It has negligible affinity for other serotonin receptors such as 5-HT1D, 5-HT2A, and 5-HT2C, [26] [27] as well as the norepinephrine and dopamine transporters (Ki = 56 nM for NET and 37 nM for DAT). [5] A small clinical study found occupancy of the 5-HT1A receptor with vilazodone, whereas occupancy of the SERT by vilazodone in humans does not seem to have been studied. [28] [29] [30]

Pharmacokinetics

Vilazodone is best absorbed with food and has a bioavailability of 72% under fed conditions. The Cmax increased between 147 and 160% and the AUC increased between 64 and 85% of vilazodone when it was administered with either a fatty or light meal. [31]

History

It was developed by Merck KGaA and licensed by Clinical Data, a biotech company purchased by Forest Laboratories in 2011. [32]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Venlafaxine</span> Antidepressant medication

Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic neuropathic pain. It is taken orally. It is also available as the salt venlafaxine besylate in an extended-release formulation.

<span class="mw-page-title-main">Duloxetine</span> Antidepressant medication used also for treatment of anxiety and chronic pain

Duloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, fibromyalgia, neuropathic pain and central sensitization. It is taken by mouth.

<span class="mw-page-title-main">Serotonin–norepinephrine reuptake inhibitor</span> Class of antidepressant medication

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. Off-label uses include treatments for attention-deficit hyperactivity disorder (ADHD), and obsessive–compulsive disorder (OCD). SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters.

<span class="mw-page-title-main">Azapirone</span> Drug class of psycotropic drugs

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

<span class="mw-page-title-main">Pindolol</span> Chemical compound

Pindolol, sold under the brand name Visken among others, is a nonselective beta blocker which is used in the treatment of hypertension. It is also an antagonist of the serotonin 5-HT1A receptor, preferentially blocking inhibitory 5-HT1A autoreceptors, and has been researched as an add-on therapy to various antidepressants, such as clomipramine and the selective serotonin reuptake inhibitors (SSRIs), in the treatment of depression and obsessive-compulsive disorder.

<span class="mw-page-title-main">Trazodone</span> Antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication, used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.

<span class="mw-page-title-main">Milnacipran</span> Antidepressant

Milnacipran is a serotonin–norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatment of major depressive disorder in the US, but it is in other countries.

<span class="mw-page-title-main">Olanzapine/fluoxetine</span> Antidepressant medication

Olanzapine/fluoxetine is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.

<span class="mw-page-title-main">Fluoxetine</span> SSRI antidepressant

Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder (OCD), anxiety, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is also approved for treatment of major depressive disorder in adolescents and children 8 years of age and over. It has also been used to treat premature ejaculation. Fluoxetine is taken by mouth.

<span class="mw-page-title-main">Gepirone</span> Medication used for major depressive disorder

Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally.

<span class="mw-page-title-main">Serotonin reuptake inhibitor</span> Class of drug

A serotonin reuptake inhibitor (SRI) is a type of drug which acts as a reuptake inhibitor of the neurotransmitter serotonin by blocking the action of the serotonin transporter (SERT). This in turn leads to increased extracellular concentrations of serotonin and, therefore, an increase in serotonergic neurotransmission. It is a type of monoamine reuptake inhibitor (MRI); other types of MRIs include dopamine reuptake inhibitors and norepinephrine reuptake inhibitors.

<span class="mw-page-title-main">Serotonin antagonist and reuptake inhibitor</span> Class of drug

Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.

<span class="mw-page-title-main">Vortioxetine</span> Serotonin modulator antidepressant

Vortioxetine, sold under the brand name Trintellix and Brintellix among others, is an antidepressant of the serotonin modulator and stimulator (SMS) class. Its effectiveness is viewed as similar to that of other antidepressants. It is taken orally.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

A serotonin modulator and stimulator (SMS), sometimes referred to more simply as a serotonin modulator, is a type of drug with a multimodal action specific to the serotonin neurotransmitter system. To be precise, SMSs simultaneously modulate one or more serotonin receptors and inhibit the reuptake of serotonin. The term was created to describe the mechanism of action of the serotonergic antidepressant vortioxetine, which acts as a serotonin reuptake inhibitor (SRI), agonist of the 5-HT1A receptor, and antagonist of the 5-HT3 and 5-HT7 receptors. However, it can also technically be applied to vilazodone, which is an antidepressant as well and acts as an SRI and 5-HT1A receptor partial agonist.

References

  1. 1 2 3 4 5 6 7 8 9 "Vilazodone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.
  2. ↑ Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
  3. ↑ "Viibryd Product information". Health Canada. April 25, 2012. Retrieved June 10, 2022.
  4. ↑ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada . May 4, 2016. Retrieved April 7, 2024.
  5. 1 2 3 4 5 6 7 "Viibryd (vilazodone hydrochloride) tablet Viibryd (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]". DailyMed. Forest Laboratories, Inc. December 2012. Archived from the original on October 29, 2013. Retrieved October 28, 2013.
  6. 1 2 Hughes S, Lacasse J, Fuller RR, Spaulding-Givens J (September 2017). "Adverse effects and treatment satisfaction among online users of four antidepressants". Psychiatry Research. 255: 78–86. doi:10.1016/j.psychres.2017.05.021. PMID   28531820. S2CID   4572360.
  7. ↑ "Vilazodone (Viibryd) Use During Pregnancy". Drugs.com. Retrieved March 21, 2019.
  8. ↑ "Drug Product Database Online Query". Health Canada. Government of Canada. April 25, 2012. Retrieved May 18, 2020.
  9. ↑ "Vilazodone - Drug Usage Statistics". ClinCalc. Archived from the original on July 8, 2020. Retrieved October 16, 2021.
  10. ↑ "Generic Viibryd Availability".
  11. ↑ "Vilazodone: FDA-Approved Drugs".
  12. ↑ "2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). January 21, 2021. Retrieved June 10, 2022.
  13. 1 2 3 Kirsch I (2014). "Antidepressants and the Placebo Effect". Zeitschrift für Psychologie. 222 (3): 128–134. doi:10.1027/2151-2604/a000176. PMC   4172306 . PMID   25279271.
  14. 1 2 3 4 5 6 Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (August 2013). "A review of current evidence for vilazodone in major depressive disorder". International Journal of Psychiatry in Clinical Practice. 17 (3): 160–169. doi:10.3109/13651501.2013.794245. PMID   23578403. S2CID   10702028.
  15. ↑ Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, et al. (September 2011). "Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant". The Journal of Clinical Psychiatry. 72 (9): 1166–1173. doi:10.4088/JCP.11r06984. PMID   21951984.
  16. ↑ Stuivenga M, Giltay EJ, Cools O, Roosens L, Neels H, Sabbe B (February 2019). "Evaluation of vilazodone for the treatment of depressive and anxiety disorders". Expert Opinion on Pharmacotherapy. 20 (3). Informa UK Limited: 251–260. doi:10.1080/14656566.2018.1549542. hdl: 1887/3630582 . PMID   30475091. S2CID   53773793.
  17. ↑ "New Medicines Newsletter" (PDF). NHS. Archived from the original (PDF) on March 21, 2019. Retrieved March 21, 2019.
  18. ↑ Zareifopoulos N, Dylja I (April 2017). "Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis". Asian Journal of Psychiatry. 26: 115–122. doi:10.1016/j.ajp.2017.01.016. PMID   28483071.
  19. ↑ "SUPPLEMENT APPROVAL" (PDF). U.S. Food and Drug Administration (FDA).
  20. ↑ Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR (October 2011). "A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder". Journal of Clinical Psychopharmacology. 31 (5): 643–6. doi:10.1097/JCP.0b013e31822c6741. PMID   21869687.
  21. ↑ "FDA approves Clinical Data Inc's antidepressant". Reuters. January 22, 2011. Archived from the original on January 27, 2011.
  22. ↑ Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, et al. (April 2013). "Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis". JAMA Psychiatry. 70 (4): 436–443. doi: 10.1001/jamapsychiatry.2013.684 . PMID   23446732.
  23. ↑ Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM (September 2005). "Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis". Journal of Perinatology. 25 (9): 595–604. doi: 10.1038/sj.jp.7211352 . PMID   16015372.
  24. ↑ Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH (September 2009). "Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study". BMJ. 339 (sep23 1): b3569. doi:10.1136/bmj.b3569. PMC   2749925 . PMID   19776103.
  25. ↑ Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, et al. (June 2014). "Antidepressant use in pregnancy and the risk of cardiac defects". The New England Journal of Medicine. 370 (25): 2397–2407. doi:10.1056/NEJMoa1312828. PMC   4062924 . PMID   24941178.
  26. 1 2 Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, et al. (March 2005). "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology. 510 (1–2): 49–57. doi:10.1016/j.ejphar.2005.01.018. PMID   15740724.
  27. ↑ Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, et al. (September 2002). "Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 302 (3): 1220–1227. doi:10.1124/jpet.102.034280. PMID   12183683. S2CID   12020750.
  28. ↑ Dawson LA (December 2013). "The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?". Expert Opinion on Drug Discovery. 8 (12): 1529–1539. doi:10.1517/17460441.2013.855195. PMID   24195711. S2CID   19662281.
  29. ↑ Dawson LA, Watson JM (2009). "Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders". CNS Neuroscience & Therapeutics. 15 (2): 107–117. doi:10.1111/j.1755-5949.2008.00067.x. PMC   6493994 . PMID   19499624.
  30. ↑ Choi E, Zmarlicka M, Ehret MJ (September 2012). "Vilazodone: a novel antidepressant". American Journal of Health-System Pharmacy. 69 (18): 1551–1557. doi:10.2146/ajhp110374. PMID   22935937.
  31. ↑ Cruz MP (January 2012). "Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder". P & T. 37 (1): 28–31. PMC   3278186 . PMID   22346333.
  32. ↑ "Xconomy: Blend Therapeutics Taps Former Clinical Data Chief Fromkin As New CEO". xconomy.com. April 13, 2015. Archived from the original on September 9, 2017. Retrieved May 6, 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.